HLA Identical Siblings Are the Best Donors for Children with ALL  by Peters, Christina et al.
Age
(yrs)
Sex Mutation Complications post HSCT Survival
5 F TINF2 Pulmonary: Pulmonary ﬁbrosis
Renal: Hemolytic uremic syndrome,
CKD
Vascular: Venous malformations
Heme: Hypocellular marrow
Other DC related: Leukoplakia, nail
dystrophy, alopecia, lacrimal duct
stenosis, vaginal stenosis, osteoporosis,
femur fracture
Alive
4 F TINF2 Pulmonary: Pulmonary ﬁbrosis
GI: Massive GI bleeding, ascites
Renal: Hepatorenal syndrome
Heme/BMT: Hypocellular marrow
Other DC related: Lacrimal duct stenosis
Dead
5 M TINF2 GI: Massive GI bleeding, ascites
Heme/BMT: Hypocellular marrow, oral
GVHD
ID: Disseminated adenovirus
Alive
2 M TINF2 GI: Massive GI bleeding, intestinal
obstruction and perforation
Renal: Thrombotic microangiopathy,
AKI
Heme/BMT: Acute GVHD (gut,
liver,skin)
Other DC related: Urethral meatus
stenosis
ID: HHV6, C difﬁcile colitis
Dead
13 M DKC1 GI: Esophageal stricture Alive
3 M TERT Heme/BMT: Acute gut GVHD Alive
Abstracts / Biol Blood Marrow Transplant 20 (2014) S165eS183 S1792 received myeloablative conditioning regimens (MAC). Pa-
tients received HSCT from MRDs (4) and MMUDs (2). 5/6
patients engrafted with the 1st HSCT. One patient had pri-
mary engraftment failure and was rescued with a 2nd HSCT
from the same donor using MAC. 3/6 six patients developed
GVHD (acute GVHD e 2, chronic extensive GVHD -1). 4/6
patients are alive (OS: 67%) with a median follow up of 1753
days (range: 92e5963). However, all 4 patients with TINF2
mutations suffered unusual multi-system complications
which developed late (4e5 years) after HSCT. The 2 patients
with DKC1 and TERT mutation had no such atypical compli-
cations and are doing well at last follow up. Recent reports
describe a more severe phenotype in patients with TINF2
mutations and the extra-hematopoietic manifestations that
continue after transplantation suggest that HSCT can have
only limited impact on the natural course of their disease and
on their long-term outcome. These patients require close
multi-disciplinary follow up after HSCT to ensure early
detection of complications. Future improvements could
focus on the use of less toxic RIC regimens, measurement of
biomarkers to predict complications and perhaps novel
therapies to correct the underlying telomere defect.264
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Allogeneic hematopoietic stem cell transplantation (HSCT)
from unrelated donors became a common practice during
the last years to rescue children and adolescents with high
risk acute lymphoblastic leukaemia (ALL) who lack an HLA
identical sibling donor (MSD). However, heterogeneous ap-
proaches in donor selection and transplantation methods
hamper the interpretation of available data. Therefore we
compared the inﬂuence of donor source under standardized
methods. Twenty-nine centres participated in the prospec-
tive trial to evaluate whether the results of HSCT from HLA
matched donors (MD) are comparable to those of HLA
identical siblings in patients with high risk ALL.
118 patients (age 0.5-18 years, med. 10.2) underwent MSD-
HSCT and 313 MD-HSCT. 218 pts were in ﬁrst and 213
beyond 1st remission. Unrelated donors were compatible
for at least 9/10 matches with allelic typing. GvHD-pro-
phylaxis consisted of CSA only after MSD-HSCT and of CSA/
MTX/ATG after MD-HSCT. Patients older than 2 years
received total body irradiation and etoposide as condi-
tioning regimen. The stem cell source was for 82% of the
MSD-group bone marrow (BM), 10% received peripheral
blood stem cells (PBSC) and some received cord blood (CB).
In the MD-cohort, 66% received BM, 28% PBSC and the
remaining CB or combinations.
Results: After a median follow up of 4.2 years, the 4-year
disease free survival (DFS) is 0.700.04, the overall survival
(OS) 0.770.04 after MSD-HSCT and after MD-HSCT DFS is
0.660.03, OS 0.730.03 (n.s.); 4-years relapse-incidence is
0.220.04 after MSD-HSCT and 0.230.02 after MD-HSCT
(n.s.). Non-relapse mortality at 4 years is 0.060.02 for MSD
and 0.100.02 for MD (p-value 0.228). In multivariate anal-
ysis the only signiﬁcant impact on OS and DFS was 1st
remission compared to 2nd or 3rd remission with a Hazard
ratio of 1.71. However, engraftment was signiﬁcantly better
after MSD-HSCT: the median day to reach ANC >1000/ml/
lymphocytes >100/ml/platelets >50.000/ml was 17/14/22 af-
ter MSD-HSCT and 22/23/32 after MD-HSCT (p < 0.001). This
resulted in signiﬁcant less severe infections (  grade 3 CTA
3.0) e18% vs. 40% (p < 0.01) and less severe pulmonary
complications: 10% vs. 19% (p ¼ 0.034).
Abstracts / Biol Blood Marrow Transplant 20 (2014) S165eS183S180We conclude that despite excellent outcome with low
GVHD-incidence and low NRM after HSCT from MD in chil-
dren with high risk ALL the HSCT von MSD results in faster
engraftment and immunoreconstitution and less severe in-
fections and justiﬁes the use of minor sibling donors.265
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Background: JMML is a rare, highly aggressive clonal
myeloproliferative disorder typically diagnosed in infants
and young children. Allogeneic HSCT is widely accepted as
the standard curative therapy for JMML, but success is
limited by engraftment failure or disease relapse. Five-year
overall survival ranges from 50-55%.
Objective: Evaluate our single center allogeneic HSCT out-
comes for JMML.
Methods: We retrospectively reviewed data on all JMML
patients who received allogeneic HSCT at our center from
1998-2013. Data collected were age at diagnosis and HSCT,
time to HSCT, sex, race/ethnicity, conditioning regimen, stem
cell source, total nucleated cell dose, graft-versus-host dis-
ease (GVHD) prophylaxis, time to neutrophil (absolute
neutrophil count, ANC) and platelet (PLT) engraftment,
presence of acute and/or chronic GVHD, relapse, cause of
death, and last time of follow-up. Descriptive statistics were
used for data analysis.
Results: Eleven patients were diagnosed with JMML and
received allogeneic HSCT over the last 15 years in our center.
Median age at diagnosis was 18.6 (range 2.9-42.1) months.
Six of 11 (54.5%) were males. Eight of 11 (72.7%) were His-
panic, 2/11 White (18.2%), and 1/11 Black (9.1%). Median age
at HSCT was 26.2 months (range 4.1-51.0) with median time
to HSCT 6.1 months (range 1.2-17.1). All received myeloa-
blative conditioning; 8/11 (72.7%) received busulfan, cyclo-
phosphamide, and melphalan with 5/11 (45.5%) receiving
ATG. GVHD prophylaxis was CsA+steroids (4), CsA+MMF (1),
and CsA+MTX (1) and tacrolimus+MTX (5). Stem cell source
was unrelated umbilical cord blood (UCB) (7) and bone
marrow (BM) (4). UCB HLA-disparities were 5/6 (5), 4/6 (1),
and 3/6 (1). Three of 4 received matched related donor
(MRD) BMwhile 1 received matched unrelated donor (MUD)
BMT. Median time to ANC > 500/mL was 21 days, to PLT
>20,000/mL was 33 days, and to PLT >50,000/mL was 44.5
days. One patient (UCB) had engraftment failure and
received a 2nd HSCT with UCB after 200 cGy total body
irradiation+ﬂudarabine+ATG. Acute GVHD occurred in 6/11
(54.5%), limited chronic GVHD in 2/11 (18.2%) and extensive
chronic GVHD in 1/11 (9.1%). With a median follow-up of 4.2
(range_0.1-15.2) years, 8/11 patients are alive (72.7%). Cause
of death was progression to AML (1), sinusoidal obstructive
liver syndrome and HHV6 encephalitis (1) and chronic GVHD
with bronchiolitis obliterans (1).
Conclusions: The overall survival for JMML in our center
(72.7%) over the last 15 years is comparable to published
data. Despite historically poor disease-free survival, nopatients have experienced recurrent JMML post-HSCT in our
cohort. We hypothesize that this observed trend toward
superior survival may be due to undeﬁned favorable char-
acteristics in our predominantly Hispanic patient population
and younger age at diagnosis. Our experience supports the
use of HLA-mismatched UCB for unrelated donor HSCT in
JMML.
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Introduction: Failure to harvest sufﬁcient stem cells from
either Bone marrow (BM) or peripheral blood is a rare but
known impasse in stem cell transplantation (SCT). If second
boost is not given within 96 hours then chances of rejection
post second SCT are very high. Plerixafor (Mozobil) is an
effective drug for rapid (within 24 hr) stem cell mobilizer as
it reduces CD34+ hematopoietic stem cells anchoring to the
BM microenvironment through reversible inhibition of the
SDF-1a/CXCR4 axis.
Case: A 4-year-old girl of thalassemia major underwent allo-
SCT from a 6/6 loci HLA-identical 17 year old sister. Pre-
transplant work-up showed no discernible pathology except
bidirectional major ABO mismatch. Conditioning regimen
consisted of intravenous busulphan (12.8 mg/kg),cyclo-
phosphamide (200mg/kg) and ATG (90mg/kg). Pre depletion
and after red cell and plasma depletion, harvested CD34+ cell
dose was 2 and 0.5 million/kg/recipient respectively. In view
of the failed BM harvest, a decision was eventually made,
after obtaining the consent of the parents, to attempt donor
CD34+ cell mobilization with plerixafor and G-CSF. The
donor received G-CSF (5 mcg/kg s.c.) for 3 consecutive days
at 1800 hr, while plerixafor (240 mcg/kg s.c.) was given 15 hr
later, after last dose of G-CSF. Five hour after plerixafor
dosing, the donor’s WBC had reached 64.0 x 109/L. The har-
vested CD34+ cell dose of 17.6 x 106/kg/recipient infused.
Donor tolerated plerixafor well without any adverse effects.
Her neutrophil and platelets engrafted on day +19 and +21
respectively. The patient and donor remain well 2 months
after SCT. Donor would be followed every 6 monthly for next
3 years for any long term adverse effects of plerixafor.
Conclusion: Our case highlights that plerixafor is an effec-
tive agent for rapid PBSC mobilization from a normal healthy
donor, if initial BM harvest fails. However, donor should be
monitored for the long term safety of plerixafor.
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Background: Although management of CML has changed
dramatically in the era of tyrosine kinase inhibitors (TKIs),
